Looking for a District of Columbia Cimzia attorney? Get in touch with one of our District of Columbia Cimzia attorneys now.
Home : Unsafe Drugs : Cimzia : MSN Newsfeeds
Cimzia - MSN Newsfeeds
- or Europe for leading biopharmaceutical company partners, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia. Nektar has created a robust pipeline of ...
- or Europe for leading biopharmaceutical company partners, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia. Nektar has created a robust pipeline of ...
- Brian’s experience includes many years in progressively responsible sales and managed care positions at Bristol-Myers Squibb, contributing to the launch of Cimzia as Area Director Managed Markets at UCB Inc, and most recently at Savient ...
- XOMA's technologies have contributed to the success of marketed antibody products, including LUCENTIS(R) (ranibizumab injection) for wet age-related macular degeneration and CIMZIA(R) (certolizumab pegol) for rheumatoid arthritis and Crohn's disease ...
- The Company received royalties from products utilizing its proprietary PEG technology; PEGINTRON, Macugen, CIMZIA. Royalties on PEGINTRON, marketed by Merck, to comprise the majority of the Company's continuing royalty revenue. Research and ...
- XOMA's technologies have contributed to the success of marketed antibody products, including LUCENTIS(R) (ranibizumab injection) for wet age-related macular degeneration and CIMZIA(R) (certolizumab pegol) for rheumatoid arthritis and Crohn's disease ...
- Cimzia 75 Overview 76 Sales forecast 77 UCB's novel anti-TNF mAb finally gets green light 77 Non-responder patient population and pricing offer key route to uptake 78 Cimzia is back in Phase III for Crohn's disease in the EU - Datamonitor updated its ...
- Recent launches of Cimzia, Simponi and Lodotra may boost the Rheumatoid arthritis market significantly. For further details on this report, please or add the below link to your browser http://www.global-market-research-data.com/Categor...
- Viron's second therapeutic candidate, VT-346, is a powerful inhibitor of TNF-a, the therapeutic target of Enbrel(TM), Humira(TM), Cimzia(TM) and Remicade(TM), which together share a market estimated at over $20 billion annually. In head to head ...
- There is increased competition between Remicade, Humira, and the recently approved product Cimzia to be the market leader. Humira and Cimzia are presenting tough competition to Remicade, which has been in the market the longest. Tysabri has a ...
- XOMA's technologies have contributed to the success of marketed antibody products, including LUCENTIS(R) (ranibizumab injection) for wet age-related macular degeneration and CIMZIA(R) (certolizumab pegol) for rheumatoid arthritis and Crohn's disease ...
- Awareness of both new TNF antagonists was nearly universal among the respondents. The initial favorability rating noted in baseline research in May 2009 for Centocor's Simponi decreased during subsequent waves of research and now trails UCB's Cimzia ...
- And for those of us living with rheumatoid arthritis, it was a year of exciting research and more hope, as new biologics entered the arena: Simponi, Cimzia, Rituxan. The Writers & What They Wrote And here on MyRACentral, it was also a year of new ...
- or Europe for leading biopharmaceutical company partners, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Sign Up for The Penny Stock Picks' FREE Penny ...
- Humira, UCB's Cimzia) may lead to slower growth for Remicade in the future, our survey results make it clear that physicians prescribe Remicade based on its perceived superior efficacy in inducing remission and in healing fistulizing forms of Crohn's ...
- or Europe for leading biopharmaceutical company partners, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Nektar has created a robust pipeline of ...
- Cimzia. This medication was approved in 2009 for the treatment of moderate to severe Crohn's Disease for patients who have not been helped enough by the usual treatments, and also for moderate to severe rheumatoid arthritis. 5. Arzerra.
- There is increased competition between Remicade, Humira, and the recently approved product Cimzia to be the market leader. Humira and Cimzia are presenting tough competition to Remicade, which has been in the market the longest. Tysabri has a ...
- Humira, UCB's Cimzia) may lead to slower growth for Remicade in the future, our survey results make it clear that physicians prescribe Remicade based on its perceived superior efficacy in inducing remission and in healing fistulizing forms of Crohn's ...
- XOMA's technologies have contributed to the success of marketed antibody products, including LUCENTIS(R) (ranibizumab injection) for wet age-related macular degeneration and CIMZIA(R) (certolizumab pegol) for rheumatoid arthritis and Crohn's disease ...
Looking for a District of Columbia Cimzia attorney? Get in touch with one of our District of Columbia Cimzia attorneys now.
Pages: 1 2 3 4 5 6 ... Next
